Literature DB >> 10981177

Treatment of white coat hypertension.

S G Chrysant1.   

Abstract

White coat hypertension has been defined as the persistent elevation of blood pressure at the clinic or office only. It usually implies that daily ambulatory blood pressure is normal. The accepted cutoff for normal daytime ambulatory blood pressure is 135/85 mm Hg. The prevalence of white coat hypertension is high and varies from 20% to 45%. It appears to be more frequent in women, older patients, and persons with mild hypertension. White coat hypertension should not be confused with the white coat effect. The white coat effect signifies the difference in blood pressure between the office and daytime ambulatory blood pressure and occurs in patients with white coat hypertension as well as in patients with sustained hypertension that is treated or untreated. White coat hypertension is a benign condition, and the incidence of target-organ damage or cardiovascular morbidity and death is not significantly different from that in normotensive persons. Pharmacologic treatment should be withheld; instead, treatment should consist of lifestyle modification, moderate salt restriction, weight reduction, regular exercise, smoking cessation, and correction of glucose and lipid abnormalities. In addition, semiannual or annual follow-up with ambulatory blood pressure monitoring is advised.

Entities:  

Mesh:

Year:  2000        PMID: 10981177     DOI: 10.1007/s11906-000-0046-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  55 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  How common is white coat hypertension?

Authors:  T G Pickering; G D James; C Boddie; G A Harshfield; S Blank; J H Laragh
Journal:  JAMA       Date:  1988-01-08       Impact factor: 56.272

3.  Benazepril versus felodipine as supplement to bendroflumethiazide: evaluation by office and ambulatory blood pressure.

Authors: 
Journal:  Blood Press Monit       Date:  1998-04       Impact factor: 1.444

4.  White-coat hypertension as a cause of cardiovascular dysfunction.

Authors:  S K Glen; H L Elliott; J L Curzio; K R Lees; J L Reid
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

5.  A new approach to define the upper normal limits of ambulatory blood pressure.

Authors:  P Palatini; A C Pessina
Journal:  J Hypertens Suppl       Date:  1990-12

6.  Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study.

Authors:  P Palatini; P Mormino; M Santonastaso; L Mos; M Dal Follo; G Zanata; A C Pessina
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

7.  White-coat hypertension: a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study.

Authors:  P Palatini; F Dorigatti; E Roman; P Giovinazzo; D Piccolo; G De Venuto; M Mattarei; E Cozzutti; S Gregori; P Mormino; A C Pessina
Journal:  J Hypertens       Date:  1998-07       Impact factor: 4.844

8.  Ambulatory blood pressure and prognosis: summary of ongoing studies.

Authors:  D L Clement; M De Buyzere; D D Duprez
Journal:  J Hypertens Suppl       Date:  1991-12

9.  Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension.

Authors:  A Høegholm; L E Bang; K S Kristensen; J W Nielsen; J Holm
Journal:  Hypertension       Date:  1994-07       Impact factor: 10.190

10.  Prognostic value of ambulatory blood pressure measurements: further analyses.

Authors:  D Perloff; M Sokolow; R M Cowan; R P Juster
Journal:  J Hypertens Suppl       Date:  1989-05
View more
  3 in total

Review 1.  Guiding antihypertensive treatment decisions using ambulatory blood pressure monitoring.

Authors:  Giuseppe Mancia; Gianfranco Parati
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

2.  Out-of-office blood pressure: from measurement to control.

Authors:  Jean-Philippe Baguet
Journal:  Integr Blood Press Control       Date:  2012-05-16

3.  Impact of white-coat hypertension on microvascular complications in type 2 diabetes.

Authors:  Caroline K Kramer; Cristiane B Leitão; Luís H Canani; Jorge L Gross
Journal:  Diabetes Care       Date:  2008-09-03       Impact factor: 19.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.